nodriga 140 mg
alkaloid-int d.o.o. - slovenia - dasatinibum - compr. film. - 140mg - inhibitori de protein-kinaza
nodriga 20 mg
alkaloid-int d.o.o. - slovenia - dasatinibum - compr. film. - 20mg - inhibitori de protein-kinaza
nodriga 50 mg
alkaloid-int d.o.o. - slovenia - dasatinibum - compr. film. - 50mg - inhibitori de protein-kinaza
nodriga 70 mg
alkaloid-int d.o.o. - slovenia - dasatinibum - compr. film. - 70mg - inhibitori de protein-kinaza
sprycel 100 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 100mg - inhibitori de protein-kinaza
sprycel 20 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 20mg - inhibitori de protein-kinaza
sprycel 50 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 50mg - inhibitori de protein-kinaza
sprycel 70 mg
bristol-myers squibb - franta - dasatinibum - compr. film. - 70mg - inhibitori de protein-kinaza
bosulif
pfizer europe ma eeig - bosutinib (sub formă de monohidrat) - leucemie mieloidă - antineoplastic agents, protein kinase inhibitors - bosulif este indicat pentru tratamentul pacienților adulți cu:nou‑diagnosticat în fază cronică (pc) cu cromozom philadelphia pozitiv leucemie mieloidă cronică (lmc ph+). cp, faza accelerată (ap), și faza blastică (bp) lmc ph+ tratați anterior cu unul sau mai multe inhibitor de tirozin kinaza(s) [tki(s)] și pentru care imatinib, nilotinib și dasatinib nu sunt considerate adecvate opțiuni de tratament.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vezi secțiunile 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.